Rhodia to Invest in Contract Manufacturing.

Chemical Market Reporter, March, 2000 by MILMO, SEAN

RHODIA PLANS to invest [epsilon]30 million ($30 million) this year in facilities for pharmaceutical contract manufacturing to help it meet its target of a four-fold increase in custom synthesis sales, to [epsilon]120 million, by 2004. The investments will enable Rhodia to offer pharmaceutical companies a production capability stretching from pre-clinical samples to the commercial-scale manufacture of ingredients for the launch of new drugs.

Two of the company's projects involve an expansion and modernization of units at Holmes Chapel and Dagenham in England. The plants were formerly owned by Rhone-Poulenc Rorer, the pharmaceuticals arm of Rhone-Poulenc, Rhodia's former parent and now part of Aventis. Until Rhodia acquired the two facilities...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here